Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Rituximab a promising option in JIA patients failing other therapies

24 Nov 2018

Rituximab appears to be effective in the treatment of children with juvenile idiopathic arthritis (JIA) who have not responded to a tumour necrosis factor inhibitor (TNFi), a study has shown. Moreover, serious infection rates are low.

The present analysis included a real-world cohort of 41 JIA patients within the UK Biologics for Children with Rheumatic Diseases study initiating rituximab. Assessments included disease activity (at baseline and follow-up), the total number of courses each patient received, and serious infections and infusion reactions following treatment.

The median age of the cohort was 15 years, and 80 percent were female. Most of the patients had polyarthritis—rheumatoid factor (RF)-negative polyarthritis (35 percent), RF-positive polyarthritis (33 percent) or extended oligoarthritis (23 percent)—with a median disease duration of 9 years.

From rituximab initiation, the clinical Juvenile Arthritis Disease Activity Score (cJADAS; three-variable 71-joint JADAS) improved by a median of 9 units (IQR, −14 to 2; n=7). More than half of the patients received more than one course of treatment: 17 (41 percent) had one, 12 (29 percent) had two, seven (17 percent) had three, and five (12 percent) had four or more. The median time between each treatment course was 219 days (IQR, 198–315).

During follow-up, 17 patients (41 percent) reported switching to another biologic, including tocilizumab (n=8), abatacept (n=6) and TNFi (n=3).

In terms of safety, three patients (7 percent) developed a serious infection on rituximab, yielding a first serious infection rate of 6.2 per 100 person-years. There were four patients (10 percent) who had an infusion reaction.

The present data, although reassuring, highlight a need for a clinical trial of rituximab to establish clear efficacy and safety in patients with JIA, as well as to identify in which International League of Associations for Rheumatology (ILAR) categories the drug may be most effective, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.